Webinar on the various mechanisms of support offered by NIAID to facilitate discovery and development of anti-infectives

21 February 2019
Time: 17:00-18:30 CET

REVIVE is an online space to connect and support the antimicrobial R&D community. REVIVE’s aims are to facilitate learning, connect people, and share knowledge. The REVIVE webinar series on antimicrobial drug discovery and R&D is brought to you by GARDP’s Antimicrobial Memory Recovery & Exploratory Programme.

 

REVIVE Webinar Series

NIAID resources to facilitate discovery & development of anti-infectives

Moderator: François Franceschi, Project leader AMREP, GARDP

Speakers:

  • Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH
  • Dan Pevear, Senior Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals Incorporated

In this presentation, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines, and diagnostics targeting infectious diseases. The types of support that will be discussed are grants and contracts, as well as preclinical and clinical research services that aim to reduce risk and advance product development efforts. Researchers from any country and from any type of institution (academia, industry, non-profit) are eligible to apply for nearly all types of support mechanisms offered by NIAID, irrespective of prior or current NIH funding.

Ann’s presentation will be complemented by a short presentation by Dan Pevear, Senior Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals, in which he will share VenatoRx’ experience with NIAID support mechanisms.

 

More information

If you have questions or comments, please let us know. Do so by using the ‘question’ pane on the webinar control panel during the live webinar or send your questions beforehand or afterwards to: info.revive@dndi.org.